LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Strona główna・Stock List・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Closed

14.06 -0.57

Buy Sell

Overview

Share price change

24h

Current

Min

13.94

Max

14.1

Key metrics
By Trading Economics
Income	35M 9.5M
Sales	35M 94M
EPS	0.06
Profit margin	10.157
Employees	619
EBITDA	35M 17M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+31.7% upside

Market Stats
By TradingEconomics
Market Cap	-395M 2.2B
Previous open	14.63
Previous close	14.06

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

8.81 / 10.18 Support & Resistance

Adaptive Biotechnologies Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 lis 2025, 17:45 UTC

Earnings

Major Market Movers

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 lis 2025, 17:31 UTC

Earnings

Major Market Movers

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

15 lis 2025, 18:03 UTC

Earnings

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- UPDATED -- WSJ

15 lis 2025, 15:43 UTC

Earnings

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- WSJ

15 lis 2025, 12:00 UTC

Earnings

Meta Opens Pop-Up Stores to Build Buzz for Its AI Glasses -- WSJ

15 lis 2025, 09:20 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

15 lis 2025, 09:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

15 lis 2025, 00:08 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 lis 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 lis 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 lis 2025, 22:35 UTC

Earnings

Acquisitions, Mergers, Takeovers

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 lis 2025, 22:32 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 lis 2025, 22:29 UTC

Earnings

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 lis 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 lis 2025, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

14 lis 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 lis 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 lis 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 lis 2025, 20:17 UTC

Acquisitions, Mergers, Takeovers

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 lis 2025, 19:29 UTC

Market Talk

Earnings

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 lis 2025, 18:44 UTC

Market Talk

Earnings

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 lis 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14 lis 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 lis 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 lis 2025, 17:20 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

14 lis 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

14 lis 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 lis 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14 lis 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 lis 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

Peer Comparison

Price change

Adaptive Biotechnologies Corp Forecast

Price Target

By TipRanks

31.7% upside

12 Months Forecast

Average 18.57 USD 31.7%

High 22 USD

Low 14 USD

Based on 8 Wall Street analysts offering 12 month price targets forAdaptive Biotechnologies Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Adaptive Biotechnologies Corp - Dist in the past 3 months.

Technical Score

By Trading Central

8.81 / 10.18Support & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.